In type 2 diabetes mellitus people with acute coronary syndrome, there is a considerably minimized chance of major adverse cardiovascular outcomes encompassing all-cause mortality with Ticagrelor than Clopidogrel.

This study was carried out to systematically evaluate the cardiovascular outcomes reported with Ticagrelor vs Clopidogrel in type 2 diabetes mellitus (T2DM) people suffering from acute coronary syndrome (ACS).

In this meta-analysis, electronic databases were searched for articles comparing the cardiovascular outcomes seen with Ticagrelor with Clopidogrel in T2DM-affected people. RevMan 5.4 software was used to conduct the statistical analysis. The data were examined using a statistical model with a random effect. Using risk ratios (RR) and 95% confidence intervals, the results were presented.

A total of 5868 T2DM patients were incorporated, of whom 3924 participants received Clopidogrel and 1944 participants received Ticagrelor. Ticagrelor, when compared to Clopidogrel, had a considerably decreased risk of cardiac death (RR: 0.60), major adverse cardiac events (MACEs) (RR: 0.64), and all-cause mortality (RR: 0.65). But, the risks of stroke (RR: 0.56), stent thrombosis (RR: 0.70), reinfarction (RR: 0.85), and recurrent revascularization (RR: 1.48) were comparable. While the risk for major bleeding (RR: 1.08) was not statistically different, Ticagrelor was linked to a considerably greater risk of minor bleeding (RR: 1.53).

A considerably decreased major adverse cardiovascular events risks, encompassing all-cause mortality, was seen with Ticagrelor use compared to Clopidogrel use in T2DM patients with ACS. But, T2DM people who were given Ticagrelor demonstrated a noticeably raised risk of minor bleeding.